MGTA News and Press, Magenta Therapeutics Inc. From 08/02/22

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that the company will participate in a Ge...

Google is set to release earnings tomorrow, July 26. The stock boasts an attractive combination of growth and value, making it a great bargain for long-term investors. However it has some equity investments on its balance sheet, and they were down last quarter. Thanks to GAAP ...

Gainers: Vertical Aerospace ( EVTL ) +31% . NexImmune ( NEXI ) +31% . 180 Life Sciences ( ATNF ) +21% . ToughBuilt Industries ( TBLT ) +20% . Energy Vault Holdings ( NRGV ) +17% . EyePoint Pharmaceuticals ( EYPT ) +...

Gainers: Scholar Rock (SRRK) +26%. Phathom Pharmaceuticals (PHAT) +12%. 4d Pharma  (LBPS) +10%. Ocular Therapeutix (OCUL) +9%. Magenta Therapeutics (MGTA) +8%. Losers: PolarityTE (PTE) -34%. Tonix Pharmaceuticals (TNXP) -22%. Albireo Pharma (ALBO) ...

Magenta Therapeutics press release (NASDAQ:MGTA): Q1 GAAP EPS of -$0.39. Cash, cash equivalents and marketable securities as of Mar. 31 were $156.6M. Shares +4.39% PM. For further details see: Magenta Therapeutics GAAP EPS of -$0.39

– Clinical observations from preliminary data at the lowest dose of MGTA-117 in a Phase 1/2 clinical trial indicate target binding, reduction of target cells in bone marrow, rapid drug clearance and a favorable tolerability profile – – IND-enabling pre...

Gainers: Inozyme Pharma (INZY) +15%. Clarus Therapeutics (CRXT) +10%. MedAvail (MDVL) +5%. Syros Pharmaceuticals (SYRS) +5%. Magenta Therapeutics (MGTA) +4%. Losers: AlloVir (ALVR) -10%. Rite Aid (RAD) -9%. Windtree Therapeutics (WINT) -7...

Magenta Therapeutics (NASDAQ: MGTA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We are updating our MGTA company model after assuming research coverage of the company and also incorporating updates related to the company...

Clinical-stage biotech company Magenta Therapeutics (NASDAQ:MGTA) on Thursday said it would prioritize its operating plan to focus its capital allocation on its MGTA-117 targeted conditioning program. The company said the revised operating plan reduces Magenta's workforce by 14% and allows it...

– Encouraging early data and progress in MGTA-117 Phase 1/2 targeted conditioning clinical trial – – Prioritization of portfolio spending allows for extension of cash runway into Q2 2024 – Magenta Therapeutics (Nasdaq: MGTA), a clinical-st...